July 2017 - ITPC MENA

26 July 2017

IAS 2017: Closing ceremony exposes Gilead Sciences

Advocacy, ARV, HCV, Hepatitis, Intellectual Proprety, Medias 105 Views

Conference funders, Gilead Sciences, named and shamed for its “insatiable greed” Yesterday, the 9th International AIDS Conference on HIV Science in Paris (IAS 2017), drew to a close, in style. The community address delivered

25 July 2017

A new victory for ITPC-MENA : Bristol-Myers Squibb extends its voluntary license on A…

Advocacy, AIDS, Algeria, ARV, Guidelines, HIV, Intellectual Proprety, Medias, Middle East, Morocco, North Africa, Tunisia 70 Views

The 9th International AIDS Society Conference on HIV / AIDS 2017 : Bristol-Myers Squibb extends its voluntary license on Atazanavir to Egypt, a victory for ITPC-MENA Today, at the World Conference on AIDS, which

25 July 2017

BLOG: We want dolutegravir for all, and we want it now

Advocacy, AIDS, ARV, Dolutegravir, Guidelines, HIV, Middle East, North Africa 91 Views

Source: makemedicinesaffordable Author: Othoman Mellouk, Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC). Article first published on the Huffington Post here. We’re calling for a compulsory license on

24 July 2017

HIV Activists Denounce ViiV for Denying 3.5 million People Access to Optimal Treatmen…

Advocacy, AIDS, ARV, HCV, Health Financing, Hepatitis, HIV, Intellectual Proprety, Non classé 66 Views

Source : ITPC GLOBAL Today, Monday, 24 July 2017, during the 9th International AIDS Conference on HIV Science in Paris (IAS 2017), HIV treatment activists from around the world collectively blocked access to ViiV

21 July 2017

ITPC MENA IN THE REGIONAL CONSULTATION ON ACCELERATING ACCESS TO THE CONTIUUM OF HIV …

Advocacy, AIDS, ARV, Daclatasvir, Dolutegravir, Guidelines, HIV, Middle East, Morocco, North Africa 73 Views

Beirut, Lebanon, 12–14 July 2017 By the end of 2015, the estimated number of people living with HIV in the Region had reached 330 000. With a continuously growing epidemic coupled with low coverage

20 July 2017

New WHO Guidance Report- Treatment Failure and Drug Resistance

Advocacy, AIDS, ARV, Daclatasvir, Dolutegravir, Guidelines, HIV, Pathology, The Global Fund 73 Views

WHO urges action against HIV drug resistance threat 20 JULY 2017 | GENEVA – WHO alerts countries to the increasing trend of resistance to HIV drugs detailed in a report based on national surveys conducted